Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Viking therapeutics | Mind Blowing Facts

Viking Therapeutics: The High-Stakes Weight Loss Contender

Viking Therapeutics is positioning itself as a contender in the obesity market with a dual strategy of rapid clinical progress and commercial preparation.

MarketBeat

2 ‘Strong Buy’ Growth Stocks With Upside of Around 200%

These growth stocks have the potential to dramatically outperform if you are willing to bear the risks.

Barchart

This Small But Mighty Stock Could Surprise Investors in 2026

This under-the-radar biotech stock is setting up for a big 2026.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What's Up With The Jump In Viking Therapeutics Stock?

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, as well as recent positive momentum after major clinical trial developments.

Benzinga

3 Weight-Loss Drug Stocks To Consider For 2026

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Benzinga

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the SP 500 inching up 0.2% to 6,846.61, while the tech-heavy Nasdaq slipped 0.25% to 23,468.30.

Benzinga

Why Is Viking Therapeutics Stock Rising Today?

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Jim Cramer Expects Palantir To Reach New All-Time High

Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic corporate partnerships. In this volatile environment, market analysts and financial commentators provide crucial guidance to help navigate the complex landscape of investment opportunities.

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

International Business Times UK

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Benzinga

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond

Eli Lilly And Co.‘s (NYSE:LLY) recent, and highly unusual, issuance of a 40-year bond is fueling speculation that the pharmaceutical giant may be preparing for a major acquisition, with Viking Therapeutics Inc. (NASDAQ:VKTX) emerging as a potential target.

Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Benzinga

2 Growth Stocks Wall Street Predicts Will Soar 74% to 159%

With a strong pipeline, these two biotechs are poised for explosive growth.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates

Viking Therapeutics Inc (NASDAQ:VKTX) shares are falling in Wednesday’s after-hours session after the company reported financial results for the second quarter.

Barchart

2 'Strong Buy' Biotech Growth Stocks With Over 200% Upside Potential

With a strong cash position and a robust pipeline, both growth stocks are poised to generate significant long-term returns.

MarketBeat

Viking Therapeutics Stock May Struggle After As-Expected Report

Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.

MarketBeat

Viking Therapeutics Stock Pops But Struggles to Hold Gains

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

MarketBeat

Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.

Barchart

2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Kiplinger

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Barchart

Up 285% YTD, Is It Too Late to Buy This Biotech Stock?

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

Barchart

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Barchart

3 'Strong-Buy'-Rated Russell 2000 Stocks With 54% to 110% Upside

Investing in these small caps could be rewarding in the long run.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.